This retrospective observational study used data from Flatiron Health’s (NY, USA) advanced melanoma database to determine outcomes of retreatment with anti-PD-1 monotherapy for melanoma. The study concluded that patients who had received a second course of anti-PD-1 monotherapy demonstrated 100% survival at a year post-therapy administration, and had a median overall survival of 30 months.
The latest research article published in Future Oncology explores patient characteristics, treatment patterns and outcomes of advanced cutaneous melanoma patients at USA oncology practices.
Aims: To determine outcomes of retreatment with anti-PD-1 monotherapy for melanoma.
Methods: This retrospective study included adults with unresectable cutaneous melanoma who achieved stable disease (SD) or better after anti-PD-1 monotherapy and were retreated with anti-PD-1 monotherapy after ≥90-day gap. We determined overall survival (OS) and real-world tumor response (rwTR).
Results: For 21 eligible patients, from retreatment initiation, median follow-up was 14.4 months (range, 2.6-34.5); median OS was 30 months (95% CI, 14.4-not reached); 1-year survival was 100% (95% CI, 100-100%); 2-year survival was 83% (48-96%). Of 16 patients with recorded best rwTR, 10 (63%) responded (complete/partial response); 3 achieved SD; 3 had progressive disease.
Conclusions: Patients with advanced melanoma achieving SD/better after first-course anti-PD-1 monotherapy may benefit from retreatment.